{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T20:00:22Z","timestamp":1790712022961,"version":"4.1.0"},"reference-count":122,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T00:00:00Z","timestamp":1790640000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T00:00:00Z","timestamp":1790640000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Psychopharmacology"],"DOI":"10.1007\/s00213-026-07170-0","type":"journal-article","created":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T06:16:10Z","timestamp":1790662570000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Moving beyond 5-HT2A: language models map neurotransmitter receptors to experiential semantics"],"prefix":"10.1007","author":[{"given":"Praneet","family":"Suresh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josie","family":"Kins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lex","family":"Levkovskyy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Thieme","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Wren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tom","family":"Ray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederick S.","family":"Barrett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robin","family":"Carhart-Harris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danilo","family":"Bzdok","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,29]]},"reference":[{"key":"7170_CR1","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1067\/mai.2003.1585","volume":"112","author":"CA Akdis","year":"2003","unstructured":"Akdis CA, Blaser K (2003) Histamine in the immune regulation of allergic inflammation. J Allergy Clin Immunol 112:15\u201322","journal-title":"J Allergy Clin Immunol"},{"key":"7170_CR2","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.59784","volume":"9","author":"A Alamia","year":"2020","unstructured":"Alamia A, Timmermann C, Nutt DJ, VanRullen R, Carhart-Harris RL (2020) DMT alters cortical travelling waves. Elife 9:e59784","journal-title":"Elife"},{"key":"7170_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1017\/S0033291724002204","volume":"54","author":"M Angyus","year":"2024","unstructured":"Angyus M et al (2024) Validation of the imperial psychedelic predictor scale. Psychol Med 54:1\u20139","journal-title":"Psychol Med"},{"key":"7170_CR4","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1080\/02791072.2019.1593560","volume":"51","author":"MJ Baggott","year":"2019","unstructured":"Baggott MJ et al (2019) Effects of the psychedelic amphetamine MDA (3,4-Methylenedioxyamphetamine) in Healthy Volunteers. J Psychoactive Drugs 51:108\u2013117","journal-title":"J Psychoactive Drugs"},{"key":"7170_CR5","doi-asserted-by":"publisher","first-page":"eab16989","DOI":"10.1126\/sciadv.abl6989","volume":"8","author":"G Ballentine","year":"2022","unstructured":"Ballentine G, Friedman SF, Bzdok D (2022) Trips and neurotransmitters: Discovering principled patterns across 6850 hallucinogenic experiences. Sci Adv 8:eab16989","journal-title":"Sci Adv"},{"key":"7170_CR6","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1007\/s11920-022-01363-y","volume":"24","author":"GS Barber","year":"2022","unstructured":"Barber GS, Aaronson ST (2022) The emerging field of psychedelic psychotherapy. Curr Psychiatry Rep 24:583\u2013590","journal-title":"Curr Psychiatry Rep"},{"key":"7170_CR7","doi-asserted-by":"publisher","DOI":"10.1016\/j.neurot.2024.e00322","volume":"21","author":"BR Barksdale","year":"2024","unstructured":"Barksdale BR, Doss MK, Fonzo GA, Nemeroff CB (2024) The mechanistic divide in psychedelic neuroscience: an unbridgeable gap? Neurotherapeutics 21:e00322","journal-title":"Neurotherapeutics"},{"key":"7170_CR8","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1007\/7854_2017_474","volume":"36","author":"FS Barrett","year":"2018","unstructured":"Barrett FS, Griffiths RR (2018) Classic hallucinogens and mystical experiences: phenomenology and neural correlates. Curr Top Behav Neurosci 36:393\u2013430","journal-title":"Curr Top Behav Neurosci"},{"key":"7170_CR9","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.1177\/0269881115609019","volume":"29","author":"FS Barrett","year":"2015","unstructured":"Barrett FS, Johnson MW, Griffiths RR (2015) Validation of the revised Mystical Experience Questionnaire in experimental sessions with psilocybin. J Psychopharmacol 29:1182\u20131190","journal-title":"J Psychopharmacol"},{"key":"7170_CR10","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1002\/hup.2545","volume":"31","author":"JC Bouso","year":"2016","unstructured":"Bouso JC, Pedrero-P\u00e9rez EJ, Gandy S, Alc\u00e1zar-C\u00f3rcoles M\u00c1 (2016) Measuring the subjective: revisiting the psychometric properties of three rating scales that assess the acute effects of hallucinogens. Hum Psychopharmacol 31:356\u2013372","journal-title":"Hum Psychopharmacol"},{"key":"7170_CR11","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1152\/jn.00124.2024","volume":"132","author":"AT Brockett","year":"2024","unstructured":"Brockett AT, Francis NA (2024) Psilocybin decreases neural responsiveness and increases functional connectivity while preserving pure-tone frequency selectivity in mouse auditory cortex. J Neurophysiol 132:45\u201353","journal-title":"J Neurophysiol"},{"key":"7170_CR12","doi-asserted-by":"publisher","DOI":"10.1038\/s44184-024-00095-6","volume":"4","author":"A Brouwer","year":"2025","unstructured":"Brouwer A et al (2025) A qualitative analysis of the psychedelic mushroom come-up and come-down. Npj Ment Health Res 4:6","journal-title":"Npj Ment Health Res"},{"key":"7170_CR13","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1038\/s42256-019-0069-5","volume":"1","author":"D Bzdok","year":"2019","unstructured":"Bzdok D, Nichols TE, Smith SM (2019) Towards algorithmic analytics for large-scale datasets. Nat Mach Intell 1:296\u2013306","journal-title":"Nat Mach Intell"},{"key":"7170_CR14","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1016\/j.neuron.2024.01.016","volume":"112","author":"D Bzdok","year":"2024","unstructured":"Bzdok D et al (2024) Data science opportunities of large language models for neuroscience and biomedicine. Neuron 112:698\u2013717","journal-title":"Neuron"},{"key":"7170_CR15","doi-asserted-by":"publisher","first-page":"7472","DOI":"10.1523\/JNEUROSCI.1384-23.2023","volume":"43","author":"LP Cameron","year":"2023","unstructured":"Cameron LP et al (2023) Beyond the 5-HT2A receptor: classic and nonclassic targets in psychedelic drug action. J Neurosci 43:7472\u20137482","journal-title":"J Neurosci"},{"key":"7170_CR16","doi-asserted-by":"publisher","first-page":"1268","DOI":"10.1177\/0269881116662634","volume":"30","author":"TM Carbonaro","year":"2016","unstructured":"Carbonaro TM et al (2016) Survey study of challenging experiences after ingesting psilocybin mushrooms: acute and enduring positive and negative consequences. J Psychopharmacol 30:1268\u20131278","journal-title":"J Psychopharmacol"},{"key":"7170_CR17","doi-asserted-by":"publisher","first-page":"2105","DOI":"10.1038\/npp.2017.84","volume":"42","author":"RL Carhart-Harris","year":"2017","unstructured":"Carhart-Harris RL, Goodwin GM (2017) The therapeutic potential of psychedelic drugs: past, present, and future. Neuropsychopharmacology 42:2105\u20132113","journal-title":"Neuropsychopharmacology"},{"key":"7170_CR18","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1177\/0269881118754710","volume":"32","author":"RL Carhart-Harris","year":"2018","unstructured":"Carhart-Harris RL et al (2018) Psychedelics and the essential importance of context. J Psychopharmacol 32:725\u2013731","journal-title":"J Psychopharmacol"},{"key":"7170_CR19","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1007\/s00213-017-4771-x","volume":"235","author":"RL Carhart-Harris","year":"2018","unstructured":"Carhart-Harris RL et al (2018) Psilocybin with psychological support for treatment-resistant depression: six-month follow-up. Psychopharmacology 235:399\u2013408","journal-title":"Psychopharmacology"},{"key":"7170_CR20","doi-asserted-by":"publisher","DOI":"10.1186\/s13195-024-01462-3","volume":"16","author":"D Cheng","year":"2024","unstructured":"Cheng D et al (2024) N, N-Dimethyltryptamine, a natural hallucinogen, ameliorates Alzheimer\u2019s disease by restoring neuronal Sigma-1 receptor-mediated endoplasmic reticulum-mitochondria crosstalk. Alzheimers Res Ther 16:95","journal-title":"Alzheimers Res Ther"},{"key":"7170_CR21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s44184-024-00091-w","volume":"3","author":"JDC Dahan","year":"2024","unstructured":"Dahan JDC, Dadiomov D, Bostoen T, Dahan A (2024) Meta-correlation of the effect of ketamine and psilocybin induced subjective effects on therapeutic outcome. npj Mental Health Res 3:1\u20138","journal-title":"npj Mental Health Res"},{"key":"7170_CR22","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1177\/0269881118769063","volume":"32","author":"AK Davis","year":"2018","unstructured":"Davis AK, Barsuglia JP, Lancelotta R, Grant RM, Renn E (2018) The epidemiology of 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) use: Benefits, consequences, patterns of use, subjective effects, and reasons for consumption. J Psychopharmacol 32:779\u2013792","journal-title":"J Psychopharmacol"},{"key":"7170_CR23","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1038\/s41386-019-0473-x","volume":"45","author":"H de Wit","year":"2020","unstructured":"de Wit H, Bershad AK (2020) MDMA enhances pleasantness of affective touch. Neuropsychopharmacology 45:217\u2013239","journal-title":"Neuropsychopharmacology"},{"key":"7170_CR24","doi-asserted-by":"publisher","unstructured":"Dworatzyk K, Jansen T, Schmidt T (2017) Translation and validation of the german ego-dissolution inventory (EDI) and the challenging experience questionnaire (CEQ). In. https:\/\/doi.org\/10.13140\/RG.2.2.34359.01443","DOI":"10.13140\/RG.2.2.34359.01443"},{"key":"7170_CR25","doi-asserted-by":"publisher","first-page":"387","DOI":"10.3390\/neurolint13030038","volume":"13","author":"AN Edinoff","year":"2021","unstructured":"Edinoff AN et al (2021) Selective serotonin reuptake inhibitors and adverse effects: a narrative review. Neurol Int 13:387\u2013401","journal-title":"Neurol Int"},{"key":"7170_CR26","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1111\/j.1749-6632.1995.tb32388.x","volume":"763","author":"P Ernsberger","year":"1995","unstructured":"Ernsberger P et al (1995) I1-imidazoline receptors. Definition, characterization, distribution, and transmembrane signaling. Ann N Y Acad Sci 763:22\u201342","journal-title":"Ann N Y Acad Sci"},{"key":"7170_CR27","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0293349","volume":"18","author":"J Evans","year":"2023","unstructured":"Evans J et al (2023) Extended difficulties following the use of psychedelic drugs: a mixed methods study. PLoS ONE 18:e0293349","journal-title":"PLoS ONE"},{"key":"7170_CR28","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1111\/j.1469-1809.1936.tb02137.x","volume":"7","author":"RA Fisher","year":"1936","unstructured":"Fisher RA (1936) The use of multiple measurements in taxonomic problems. Ann Eugen 7:179\u2013188","journal-title":"Ann Eugen"},{"key":"7170_CR29","doi-asserted-by":"publisher","DOI":"10.3389\/fncir.2021.718348","volume":"15","author":"A Gentile Polese","year":"2021","unstructured":"Gentile Polese A, Nigam S, Hurley LM (2021) 5-HT1A receptors alter temporal responses to broadband vocalizations in the mouse inferior colliculus through response suppression. Front Neural Circuits 15:718348","journal-title":"Front Neural Circuits"},{"key":"7170_CR30","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1021\/acsptsci.2c00222","volume":"6","author":"GC Glatfelter","year":"2023","unstructured":"Glatfelter GC et al (2023) Receptor binding profiles for tryptamine psychedelics and effects of 4-propionoxy-N,N-dimethyltryptamine in mice. ACS Pharmacol Transl Sci 6:567\u2013577","journal-title":"ACS Pharmacol Transl Sci"},{"key":"7170_CR31","doi-asserted-by":"publisher","first-page":"1637","DOI":"10.1056\/NEJMoa2206443","volume":"387","author":"GM Goodwin","year":"2022","unstructured":"Goodwin GM et al (2022) Single-dose psilocybin for a treatment-resistant episode of major depression. N Engl J Med 387:1637\u20131648","journal-title":"N Engl J Med"},{"key":"7170_CR32","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.ejphar.2005.07.019","volume":"520","author":"KV Gopal","year":"2005","unstructured":"Gopal KV, Briley KA, Goodale ES, Hendea OM (2005) Selective serotonin reuptake inhibitors treatment effects on auditory measures in depressed female subjects. Eur J Pharmacol 520:59\u201369","journal-title":"Eur J Pharmacol"},{"key":"7170_CR33","doi-asserted-by":"publisher","first-page":"3224","DOI":"10.1111\/ejn.16346","volume":"59","author":"CJ Haggarty","year":"2024","unstructured":"Haggarty CJ, Bershad AK, Kumar MK, Lee R, de Wit H (2024) The 3,4-methylenedioxymethamphetamine enhances early visual processing for salient socio-emotional stimuli. Eur J Neurosci 59:3224\u20133235","journal-title":"Eur J Neurosci"},{"key":"7170_CR34","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1196\/annals.1304.001","volume":"1009","author":"A Halaris","year":"2003","unstructured":"Halaris A, Piletz JE (2003) Relevance of imidazoline receptors and agmatine to psychiatry: a decade of progress. Ann N Y Acad Sci 1009:1\u201320","journal-title":"Ann N Y Acad Sci"},{"key":"7170_CR35","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1038\/sj.npp.1300004","volume":"28","author":"CJ Harmer","year":"2003","unstructured":"Harmer CJ et al (2003) Acute SSRI administration affects the processing of social cues in healthy volunteers. Neuropsychopharmacol 28:148\u2013152","journal-title":"Neuropsychopharmacol"},{"key":"7170_CR36","doi-asserted-by":"publisher","DOI":"10.1007\/s12144-025-07415-9","author":"W He","year":"2025","unstructured":"He W, Gan J (2025) The relationship between self-reflection and mental health: a meta-analysis review. Curr Psychol. https:\/\/doi.org\/10.1007\/s12144-025-07415-9","journal-title":"Curr Psychol"},{"key":"7170_CR37","doi-asserted-by":"publisher","first-page":"204512532311763","DOI":"10.1177\/20451253231176375","volume":"13","author":"D Healy","year":"2023","unstructured":"Healy D (2023) The past, present and future of anticholinergic drugs. Ther Adv Psychopharmacol 13:20451253231176376","journal-title":"Ther Adv Psychopharmacol"},{"key":"7170_CR38","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.1001\/jamapsychiatry.2024.2546","volume":"81","author":"JT Hinkle","year":"2024","unstructured":"Hinkle JT, Graziosi M, Nayak SM, Yaden DB (2024) Adverse events in studies of classic psychedelics: a systematic review and meta-analysis. JAMA Psychiat 81:1225\u20131235","journal-title":"JAMA Psychiat"},{"key":"7170_CR39","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.1007\/s43440-023-00552-7","volume":"75","author":"J Holka-Pokorska","year":"2023","unstructured":"Holka-Pokorska J (2023) Can research on entactogens contribute to a deeper understanding of human sexuality? Pharmacol Rep 75:1381\u20131397","journal-title":"Pharmacol Rep"},{"key":"7170_CR40","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1139\/jpn.0350","volume":"28","author":"A Holt","year":"2003","unstructured":"Holt A (2003) Imidazoline binding sites on receptors and enzymes: emerging targets for novel antidepressant drugs? J Psychiatry Neurosci 28:409\u2013414","journal-title":"J Psychiatry Neurosci"},{"key":"7170_CR41","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1038\/s41386-019-0569-3","volume":"45","author":"F Holze","year":"2020","unstructured":"Holze F et al (2020) Distinct acute effects of LSD, MDMA, and D-amphetamine in healthy subjects. Neuropsychopharmacology 45:462\u2013471","journal-title":"Neuropsychopharmacology"},{"key":"7170_CR42","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.1038\/s41386-022-01297-2","volume":"47","author":"F Holze","year":"2022","unstructured":"Holze F et al (2022) Direct comparison of the acute effects of lysergic acid diethylamide and psilocybin in a double-blind placebo-controlled study in healthy subjects. Neuropsychopharmacol 47:1180\u20131187","journal-title":"Neuropsychopharmacol"},{"key":"7170_CR43","first-page":"215","volume":"93","author":"F Holze","year":"2023","unstructured":"Holze F, Gasser P, M\u00fcller F, Dolder PC, Liechti ME (2023) Lysergic acid diethylamide-assisted therapy in patients with anxiety with and without a life-threatening illness: a randomized, double-blind. Placebo-Contr Phase II Study Biol Psychiatry 93:215\u2013223","journal-title":"Placebo-Contr Phase II Study Biol Psychiatry"},{"key":"7170_CR44","unstructured":"Hough LB (1999) Histamine actions in the central nervous system. In: Basic Neurochemistry: Molecular, Cellular and Medical Aspects. 6th edition (Lippincott-Raven, 1999)"},{"key":"7170_CR45","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1038\/s41582-023-00904-0","volume":"20","author":"OD Howes","year":"2024","unstructured":"Howes OD, Bukala BR, Beck K (2024) Schizophrenia: from neurochemistry to circuits, symptoms and treatments. Nat Rev Neurol 20:22\u201335","journal-title":"Nat Rev Neurol"},{"key":"7170_CR46","doi-asserted-by":"publisher","first-page":"2177","DOI":"10.1152\/jn.00046.2006","volume":"96","author":"LM Hurley","year":"2006","unstructured":"Hurley LM (2006) Different serotonin receptor agonists have distinct effects on sound-evoked responses in inferior colliculus. J Neurophysiol 96:2177\u20132188","journal-title":"J Neurophysiol"},{"key":"7170_CR47","doi-asserted-by":"publisher","first-page":"1076459","DOI":"10.3389\/fpsyt.2022.1076459","volume":"13","author":"MI Husain","year":"2022","unstructured":"Husain MI et al (2022) Serotonergic psychedelics for depression: What do we know about neurobiological mechanisms of action? Front Psychiatry 13:1076459","journal-title":"Front Psychiatry"},{"key":"7170_CR48","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1124\/pharmrev.120.000056","volume":"73","author":"A Inserra","year":"2021","unstructured":"Inserra A, De Gregorio D, Gobbi G (2021) Psychedelics in psychiatry: neuroplastic, immunomodulatory, and neurotransmitter mechanisms. Pharmacol Rev 73:202\u2013277","journal-title":"Pharmacol Rev"},{"key":"7170_CR49","doi-asserted-by":"publisher","first-page":"3129","DOI":"10.1016\/j.neuron.2025.06.012","volume":"113","author":"MK Jain","year":"2025","unstructured":"Jain MK et al (2025) The polypharmacology of psychedelics reveals multiple targets for potential therapeutics. Neuron 113:3129-3142.e9","journal-title":"Neuron"},{"key":"7170_CR50","doi-asserted-by":"publisher","first-page":"3595","DOI":"10.1038\/s41380-023-02274-x","volume":"28","author":"AM Jaster","year":"2023","unstructured":"Jaster AM, Gonz\u00e1lez-Maeso J (2023) Mechanisms and molecular targets surrounding the potential therapeutic effects of psychedelics. Mol Psychiatry 28:3595\u20133612","journal-title":"Mol Psychiatry"},{"key":"7170_CR51","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1016\/j.pbb.2010.02.011","volume":"95","author":"CR Jesse","year":"2010","unstructured":"Jesse CR, Wilhelm EA, Bortolatto CF, Nogueira CW (2010) Evidence for the involvement of the noradrenergic system, dopaminergic and imidazoline receptors in the antidepressant-like effect of tramadol in mice. Pharmacol Biochem Behav 95:344\u2013350","journal-title":"Pharmacol Biochem Behav"},{"key":"7170_CR52","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1046\/j.1365-2044.1999.00659.x","volume":"54","author":"ZP Khan","year":"1999","unstructured":"Khan ZP, Ferguson CN, Jones RM (1999) alpha-2 and imidazoline receptor agonists. Their pharmacology and therapeutic role. Anaesthesia 54:146\u2013165","journal-title":"Anaesthesia"},{"key":"7170_CR53","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1016\/j.neuropharm.2018.02.028","volume":"142","author":"LM Klein","year":"2018","unstructured":"Klein LM, Cozzi NV, Daley PF, Brandt SD, Halberstadt AL (2018) Receptor binding profiles and behavioral pharmacology of ring-substituted N,N-diallyltryptamine analogs. Neuropharmacology 142:231\u2013239","journal-title":"Neuropharmacology"},{"key":"7170_CR54","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1097\/JCP.0b013e31817ef470","volume":"28","author":"EA Kolbrich","year":"2008","unstructured":"Kolbrich EA et al (2008) Physiological and subjective responses to controlled oral 3,4-methylenedioxymethamphetamine administration. J Clin Psychopharmacol 28:432\u2013440","journal-title":"J Clin Psychopharmacol"},{"key":"7170_CR55","doi-asserted-by":"publisher","first-page":"1425","DOI":"10.1007\/s00213-021-05999-1","volume":"239","author":"J Kuc","year":"2022","unstructured":"Kuc J et al (2022) Psychedelic experience dose-dependently modulated by cannabis: results of a prospective online survey. Psychopharmacology 239:1425\u20131440","journal-title":"Psychopharmacology"},{"key":"7170_CR56","doi-asserted-by":"publisher","DOI":"10.2466\/pms.1986.63.2.983","author":"VK Kumar","year":"1986","unstructured":"Kumar VK (1986) Measurement of phenomenological experience: phenomenology of consciousness inventory. Percept Mot Skills. https:\/\/doi.org\/10.2466\/pms.1986.63.2.983","journal-title":"Percept Mot Skills"},{"key":"7170_CR57","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1007\/s00213-017-4699-1","volume":"235","author":"KPC Kuypers","year":"2018","unstructured":"Kuypers KPC et al (2018) MDMA-induced indifference to negative sounds is mediated by the 5-HT2A receptor. Psychopharmacology 235:481\u2013490","journal-title":"Psychopharmacology"},{"key":"7170_CR58","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1038\/s41593-022-01177-4","volume":"25","author":"AC Kwan","year":"2022","unstructured":"Kwan AC, Olson DE, Preller KH, Roth BL (2022) The neural basis of psychedelic action. Nat Neurosci 25:1407\u20131419","journal-title":"Nat Neurosci"},{"key":"7170_CR59","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-022-11999-8","volume":"12","author":"DW Lawrence","year":"2022","unstructured":"Lawrence DW, Carhart-Harris R, Griffiths R, Timmermann C (2022) Phenomenology and content of the inhaled N, N-dimethyltryptamine (N, N-DMT) experience. Sci Rep 12:8562","journal-title":"Sci Rep"},{"key":"7170_CR60","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1016\/S0893-133X(00)00126-3","volume":"23","author":"ME Liechti","year":"2000","unstructured":"Liechti ME, Saur MR, Gamma A, Hell D, Vollenweider FX (2000) Psychological and physiological effects of MDMA (\u201cEcstasy\u201d) after pretreatment with the 5-HT2 Antagonist Ketanserin in healthy humans. Neuropsychopharmacol 23:396\u2013404","journal-title":"Neuropsychopharmacol"},{"key":"7170_CR61","doi-asserted-by":"publisher","DOI":"10.1186\/s10020-024-01013-4","volume":"30","author":"RV Lima da Cruz","year":"2024","unstructured":"Lima da Cruz RV, Le\u00e3o RN, Moulin TC (2024) Effects of psychedelics on neurogenesis and broader neuroplasticity: a systematic review. Mol Med 30:244","journal-title":"Mol Med"},{"key":"7170_CR62","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1007\/7854_2017_478","volume":"36","author":"JF L\u00f3pez-Gim\u00e9nez","year":"2018","unstructured":"L\u00f3pez-Gim\u00e9nez JF, Gonz\u00e1lez-Maeso J (2018) Hallucinogens and serotonin 5-HT2A receptor-mediated signaling pathways. Curr Top Behav Neurosci 36:45\u201373","journal-title":"Curr Top Behav Neurosci"},{"key":"7170_CR63","doi-asserted-by":"publisher","DOI":"10.3390\/molecules27082520","volume":"27","author":"H Lowe","year":"2022","unstructured":"Lowe H et al (2022) Psychedelics: alternative and potential therapeutic options for treating mood and anxiety disorders. Molecules 27:2520","journal-title":"Molecules"},{"key":"7170_CR64","doi-asserted-by":"publisher","first-page":"454","DOI":"10.3109\/15563650.2014.898770","volume":"52","author":"JA Lowry","year":"2014","unstructured":"Lowry JA, Brown JT (2014) Significance of the imidazoline receptors in toxicology. Clin Toxicol (Phila) 52:454\u2013469","journal-title":"Clin Toxicol (Phila)"},{"key":"7170_CR65","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1177\/02698811231196877","volume":"38","author":"LX Luan","year":"2024","unstructured":"Luan LX et al (2024) Psychological and physiological effects of extended DMT. J Psychopharmacol 38:56\u201367","journal-title":"J Psychopharmacol"},{"key":"7170_CR66","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1002\/cpt.2958","volume":"114","author":"P Mallaroni","year":"2023","unstructured":"Mallaroni P et al (2023) Assessment of the acute effects of 2C-B vs. psilocybin on subjective experience, mood, and cognition. Clin Pharmacol Ther 114:423\u2013433","journal-title":"Clin Pharmacol Ther"},{"key":"7170_CR67","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1016\/j.pbb.2007.06.001","volume":"87","author":"D Marona-Lewicka","year":"2007","unstructured":"Marona-Lewicka D, Nichols DE (2007) Further evidence that the delayed temporal dopaminergic effects of LSD are mediated by a mechanism different than the first temporal phase of action. Pharmacol Biochem Behav 87:453\u2013461","journal-title":"Pharmacol Biochem Behav"},{"key":"7170_CR68","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1177\/02698811241232548","volume":"38","author":"A Marrocu","year":"2024","unstructured":"Marrocu A et al (2024) Psychiatric risks for worsened mental health after psychedelic use. J Psychopharmacol 38:225\u2013235","journal-title":"J Psychopharmacol"},{"key":"7170_CR69","doi-asserted-by":"publisher","unstructured":"Martin D, Delgado A, Calu D (2024) The psychedelic, DOI, increases dopamine release in nucleus accumbens to predictable rewards and reward cues. 2024.03.29.587390. Preprint at https:\/\/doi.org\/10.1101\/2024.03.29.587390","DOI":"10.1101\/2024.03.29.587390"},{"key":"7170_CR70","doi-asserted-by":"publisher","unstructured":"Mikolov T, Chen K, Corrado G, Dean J (2013) Efficient estimation of word representations in vector space. Preprint at https:\/\/doi.org\/10.48550\/arXiv.1301.3781","DOI":"10.48550\/arXiv.1301.3781"},{"key":"7170_CR71","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1038\/s41386-023-01656-7","volume":"49","author":"JM Mitchell","year":"2024","unstructured":"Mitchell JM, Anderson BT (2024) Psychedelic therapies reconsidered: compounds, clinical indications, and cautious optimism. Neuropsychopharmacol 49:96\u2013103","journal-title":"Neuropsychopharmacol"},{"key":"7170_CR72","doi-asserted-by":"publisher","first-page":"2473","DOI":"10.1038\/s41591-023-02565-4","volume":"29","author":"JM Mitchell","year":"2023","unstructured":"Mitchell JM et al (2023) MDMA-assisted therapy for moderate to severe PTSD: a randomized, placebo-controlled phase 3 trial. Nat Med 29:2473\u20132480","journal-title":"Nat Med"},{"key":"7170_CR73","doi-asserted-by":"publisher","first-page":"1032","DOI":"10.1038\/s41593-023-01316-5","volume":"26","author":"R Moliner","year":"2023","unstructured":"Moliner R et al (2023) Psychedelics promote plasticity by directly binding to BDNF receptor TrkB. Nat Neurosci 26:1032\u20131041","journal-title":"Nat Neurosci"},{"key":"7170_CR74","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-60259-4","volume":"14","author":"D Nelic","year":"2024","unstructured":"Nelic D et al (2024) Agonist-selective activation of individual G-proteins by muscarinic receptors. Sci Rep 14:9652","journal-title":"Sci Rep"},{"key":"7170_CR75","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1177\/0269881118780713","volume":"32","author":"CR Nicholas","year":"2018","unstructured":"Nicholas CR et al (2018) High dose psilocybin is associated with positive subjective effects in healthy volunteers. J Psychopharmacol 32:770\u2013778","journal-title":"J Psychopharmacol"},{"key":"7170_CR76","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1080\/02791072.1986.10472362","volume":"18","author":"DE Nichols","year":"1986","unstructured":"Nichols DE (1986) Differences between the mechanism of action of MDMA, MBDB, and the classic hallucinogens. Identification of a new therapeutic class: entactogens. J Psychoactive Drugs 18:305\u2013313","journal-title":"J Psychoactive Drugs"},{"key":"7170_CR77","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1124\/pr.115.011478","volume":"68","author":"DE Nichols","year":"2016","unstructured":"Nichols DE (2016) Psychedelics. Pharmacol Rev 68:264\u2013355","journal-title":"Pharmacol Rev"},{"key":"7170_CR78","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2022.863088","volume":"13","author":"DE Nichols","year":"2022","unstructured":"Nichols DE (2022) Entactogens: how the name for a novel class of psychoactive agents originated. Front Psychiatry 13:863088","journal-title":"Front Psychiatry"},{"key":"7170_CR79","doi-asserted-by":"publisher","DOI":"10.3389\/fnhum.2016.00269","author":"MM Nour","year":"2016","unstructured":"Nour MM, Evans L, Nutt D, Carhart-Harris RL (2016) Ego-dissolution and psychedelics: validation of the ego-dissolution inventory (EDI). Front Hum Neurosci. https:\/\/doi.org\/10.3389\/fnhum.2016.00269","journal-title":"Front Hum Neurosci"},{"key":"7170_CR80","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuroimage.2024.120718","volume":"297","author":"ML Pais","year":"2024","unstructured":"Pais ML et al (2024) Rapid effects of tryptamine psychedelics on perceptual distortions and early visual cortical population receptive fields. Neuroimage 297:120718","journal-title":"Neuroimage"},{"key":"7170_CR81","doi-asserted-by":"publisher","unstructured":"Pennington J, Socher R, Manning C (2014) GloVe: global vectors for word representation. In: Proceedings of the 2014 conference on empirical methods in natural language processing (EMNLP) (eds Moschitti, A., Pang, B. & Daelemans, W.) 1532\u20131543 (Association for Computational Linguistics, Doha, Qatar). https:\/\/doi.org\/10.3115\/v1\/D14-1162","DOI":"10.3115\/v1\/D14-1162"},{"key":"7170_CR82","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1016\/S0022-3956(03)00046-3","volume":"37","author":"JE Piletz","year":"2003","unstructured":"Piletz JE et al (2003) Differential expression of alpha2-adrenoceptor vs. imidazoline binding sites in postmortem orbitofrontal cortex and amygdala of depressed subjects. J Psychiatr Res 37:399\u2013409","journal-title":"J Psychiatr Res"},{"key":"7170_CR83","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.jpsychires.2006.10.011","volume":"42","author":"J Piletz","year":"2008","unstructured":"Piletz J, Baker R, Halaris A (2008) Platelet imidazoline receptors as state marker of depressive symptomatology. J Psychiatr Res 42:41\u201349","journal-title":"J Psychiatr Res"},{"key":"7170_CR84","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuroimage.2020.116733","volume":"213","author":"RLI Pillai","year":"2020","unstructured":"Pillai RLI et al (2020) Examining the underpinnings of loudness dependence of auditory evoked potentials with positron emission tomography. Neuroimage 213:116733","journal-title":"Neuroimage"},{"key":"7170_CR85","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1111\/j.1365-2125.2004.02207.x","volume":"58","author":"SK Praharaj","year":"2004","unstructured":"Praharaj SK (2004) Serotonin reuptake inhibitor induced sensory disturbances. Br J Clin Pharmacol 58:673\u2013674","journal-title":"Br J Clin Pharmacol"},{"key":"7170_CR86","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0009019","volume":"5","author":"TS Ray","year":"2010","unstructured":"Ray TS (2010) Psychedelics and the human receptorome. PLoS ONE 5:e9019","journal-title":"PLoS ONE"},{"key":"7170_CR87","unstructured":"Revised Mystical Experience Questionnaire (MEQ-30) (2012). Psychology Tools. https:\/\/psychology-tools.com\/meq-30\/"},{"key":"7170_CR88","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/S0376-8716(00)00175-7","volume":"62","author":"J Riba","year":"2001","unstructured":"Riba J, Rodr\u00edguez-Fornells A, Strassman RJ, Barbanoj MJ (2001) Psychometric assessment of the Hallucinogen rating scale. Drug Alcohol Depend 62:215\u2013223","journal-title":"Drug Alcohol Depend"},{"key":"7170_CR89","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1016\/j.euroneuro.2016.05.001","volume":"26","author":"A Rickli","year":"2016","unstructured":"Rickli A, Moning OD, Hoener MC, Liechti ME (2016) Receptor interaction profiles of novel psychoactive tryptamines compared with classic hallucinogens. Eur Neuropsychopharmacol 26:1327\u20131337","journal-title":"Eur Neuropsychopharmacol"},{"key":"7170_CR90","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1016\/j.neuropharm.2015.10.016","volume":"101","author":"MS Riga","year":"2016","unstructured":"Riga MS, Bortolozzi A, Campa L, Artigas F, Celada P (2016) The serotonergic hallucinogen 5-methoxy-N,N-dimethyltryptamine disrupts cortical activity in a regionally-selective manner via 5-HT(1A) and 5-HT(2A) receptors. Neuropharmacology 101:370\u2013378","journal-title":"Neuropharmacology"},{"key":"7170_CR91","doi-asserted-by":"publisher","DOI":"10.3389\/fnhum.2014.00204","author":"L Roseman","year":"2014","unstructured":"Roseman L, Leech R, Feilding A, Nutt DJ, Carhart-Harris RL (2014) The effects of psilocybin and MDMA on between-network resting state functional connectivity in healthy volunteers. Front Hum Neurosci. https:\/\/doi.org\/10.3389\/fnhum.2014.00204","journal-title":"Front Hum Neurosci"},{"key":"7170_CR92","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2017.00974","volume":"8","author":"L Roseman","year":"2017","unstructured":"Roseman L, Nutt DJ, Carhart-Harris RL (2017) Quality of acute psychedelic experience predicts therapeutic efficacy of psilocybin for treatment-resistant depression. Front Pharmacol 8:974","journal-title":"Front Pharmacol"},{"key":"7170_CR93","doi-asserted-by":"publisher","first-page":"1076","DOI":"10.1177\/0269881119855974","volume":"33","author":"L Roseman","year":"2019","unstructured":"Roseman L et al (2019) Emotional breakthrough and psychedelics: validation of the Emotional Breakthrough Inventory. J Psychopharmacol 33:1076\u20131087","journal-title":"J Psychopharmacol"},{"key":"7170_CR94","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1248\/bpb.b14-00315","volume":"38","author":"Y Sakashita","year":"2015","unstructured":"Sakashita Y et al (2015) Effect of psilocin on extracellular dopamine and serotonin levels in the mesoaccumbens and mesocortical pathway in awake rats. Biol Pharm Bull 38:134\u2013138","journal-title":"Biol Pharm Bull"},{"key":"7170_CR95","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1038\/s41380-024-02743-x","volume":"30","author":"J Sapienza","year":"2025","unstructured":"Sapienza J et al (2025) Psychedelics and schizophrenia: a double-edged sword. Mol Psychiatry 30:679\u2013692","journal-title":"Mol Psychiatry"},{"key":"7170_CR96","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2023.109774","volume":"245","author":"TS Saraf","year":"2024","unstructured":"Saraf TS, Chen Y, Tyagi R, Canal CE (2024) Altered brain serotonin 5-HT1A receptor expression and function in juvenile Fmr1 knockout mice. Neuropharmacology 245:109774","journal-title":"Neuropharmacology"},{"key":"7170_CR97","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1016\/j.neuron.2022.12.031","volume":"111","author":"C Sayal\u0131","year":"2023","unstructured":"Sayal\u0131 C, Barrett FS (2023) The costs and benefits of psychedelics on cognition and mood. Neuron 111:614\u2013630","journal-title":"Neuron"},{"key":"7170_CR98","doi-asserted-by":"publisher","DOI":"10.1001\/jamahealthforum.2024.3630","volume":"5","author":"O Simonsson","year":"2024","unstructured":"Simonsson O, Johnson MW, Hendricks PS (2024) Psychedelic and MDMA-related adverse effects\u2014a call for action. JAMA Health Forum 5:e243630","journal-title":"JAMA Health Forum"},{"key":"7170_CR99","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1007\/s40263-023-01014-7","volume":"37","author":"ALW Smith","year":"2023","unstructured":"Smith ALW, Harmer CJ, Cowen PJ, Murphy SE (2023) The serotonin 1A (5-HT1A) receptor as a pharmacological target in depression. CNS Drugs 37:571\u2013585","journal-title":"CNS Drugs"},{"key":"7170_CR100","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1177\/02698811241265352","volume":"38","author":"K Stocker","year":"2024","unstructured":"Stocker K, Liechti ME (2024) Methylenedioxymethamphetamine is a connectogen with empathogenic, entactogenic, and still further connective properties: it is time to reconcile \u201cthe great entactogen\u2014empathogen debate.\u201d J Psychopharmacol 38:685\u2013689","journal-title":"J Psychopharmacol"},{"key":"7170_CR101","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/0166-4328(96)00081-2","volume":"73","author":"RJ Strassman","year":"1996","unstructured":"Strassman RJ (1996) Human psychopharmacology of N,N-dimethyltryptamine. Behav Brain Res 73:121\u2013124","journal-title":"Behav Brain Res"},{"key":"7170_CR102","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1001\/archpsyc.1994.03950020022002","volume":"51","author":"RJ Strassman","year":"1994","unstructured":"Strassman RJ, Qualls CR, Uhlenhuth EH, Kellner R (1994) Dose-response study of N, N-dimethyltryptamine in humans. II. Subjective effects and preliminary results of a new rating scale. Arch Gen Psychiatry 51:98\u2013108","journal-title":"Arch Gen Psychiatry"},{"key":"7170_CR103","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0012412","volume":"5","author":"E Studerus","year":"2010","unstructured":"Studerus E, Gamma A, Vollenweider FX (2010) Psychometric evaluation of the Altered States of Consciousness Rating Scale (OAV). PLoS One 5:e12412","journal-title":"PLoS One"},{"key":"7170_CR104","unstructured":"SuperAnnotate (2024). https:\/\/www.superannotate.com\/"},{"key":"7170_CR105","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.812227","author":"E Tagliazucchi","year":"2022","unstructured":"Tagliazucchi E (2022) Language as a window into the altered state of consciousness elicited by psychedelic drugs. Front Pharmacol. https:\/\/doi.org\/10.3389\/fphar.2022.812227","journal-title":"Front Pharmacol"},{"key":"7170_CR106","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1016\/j.neuropharm.2009.06.035","volume":"57","author":"BG Taksande","year":"2009","unstructured":"Taksande BG, Kotagale NR, Tripathi SJ, Ugale RR, Chopde CT (2009) Antidepressant like effect of selective serotonin reuptake inhibitors involve modulation of imidazoline receptors by agmatine. Neuropharmacology 57:415\u2013424","journal-title":"Neuropharmacology"},{"key":"7170_CR107","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-025-88303-x","volume":"15","author":"T Tamura","year":"2025","unstructured":"Tamura T, Takagi S, Takahashi H, Sugihara G (2025) The role of self-rumination and self-reflection in depressive symptoms among individuals with attention-deficit\/hyperactivity disorder traits. Sci Rep 15:3920","journal-title":"Sci Rep"},{"key":"7170_CR108","doi-asserted-by":"publisher","first-page":"4540","DOI":"10.1523\/JNEUROSCI.4825-14.2015","volume":"35","author":"Z-Q Tang","year":"2015","unstructured":"Tang Z-Q, Trussell LO (2015) Serotonergic regulation of excitability of principal cells of the dorsal cochlear nucleus. J Neurosci 35:4540\u20134551","journal-title":"J Neurosci"},{"key":"7170_CR109","doi-asserted-by":"publisher","first-page":"26","DOI":"10.2174\/1570159X13666141210222409","volume":"13","author":"R Tittarelli","year":"2015","unstructured":"Tittarelli R, Mannocchi G, Pantano F, Romolo FS (2015) Recreational use, analysis and toxicity of tryptamines. Curr Neuropharmacol 13:26\u201346","journal-title":"Curr Neuropharmacol"},{"key":"7170_CR110","doi-asserted-by":"publisher","first-page":"981","DOI":"10.5498\/wjp.v11.i11.981","volume":"11","author":"AP Valverde","year":"2021","unstructured":"Valverde AP, Camargo A, Rodrigues ALS (2021) Agmatine as a novel candidate for rapid-onset antidepressant response. World J Psychiatry 11:981\u2013996","journal-title":"World J Psychiatry"},{"key":"7170_CR111","doi-asserted-by":"publisher","DOI":"10.1016\/j.neubiorev.2022.104793","volume":"140","author":"M van Elk","year":"2022","unstructured":"van Elk M, Yaden DB (2022) Pharmacological, neural, and psychological mechanisms underlying psychedelics: a critical review. Neurosci Biobehav Rev 140:104793","journal-title":"Neurosci Biobehav Rev"},{"key":"7170_CR112","doi-asserted-by":"publisher","first-page":"1932","DOI":"10.1038\/npp.2011.80","volume":"36","author":"JHP van Wel","year":"2011","unstructured":"van Wel JHP et al (2011) Blockade of 5-HT2 receptor selectively prevents MDMA-induced verbal memory impairment. Neuropsychopharmacology 36:1932\u20131939","journal-title":"Neuropsychopharmacology"},{"key":"7170_CR113","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0040187","volume":"7","author":"JHP van Wel","year":"2012","unstructured":"van Wel JHP et al (2012) Effects of acute MDMA intoxication on mood and impulsivity: role of the 5-HT2 and 5-HT1 receptors. PLoS ONE 7:e40187","journal-title":"PLoS ONE"},{"key":"7170_CR114","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41398-024-03074-9","volume":"14","author":"P Vizeli","year":"2024","unstructured":"Vizeli P et al (2024) Pharmacological and non-pharmacological predictors of the LSD experience in healthy participants. Transl Psychiatry 14:1\u20138","journal-title":"Transl Psychiatry"},{"key":"7170_CR115","doi-asserted-by":"publisher","first-page":"265","DOI":"10.31887\/DCNS.2001.3.4\/fxvollenweider","volume":"3","author":"FX Vollenweider","year":"2001","unstructured":"Vollenweider FX (2001) Brain mechanisms of hallucinogens and entactogens. Dialogues Clin Neurosci 3:265\u2013279","journal-title":"Dialogues Clin Neurosci"},{"key":"7170_CR116","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1055\/a-1721-2914","volume":"55","author":"FX Vollenweider","year":"2022","unstructured":"Vollenweider FX, Smallridge JW (2022) Classic psychedelic drugs: update on biological mechanisms. Pharmacopsychiatry 55:121\u2013138","journal-title":"Pharmacopsychiatry"},{"key":"7170_CR117","doi-asserted-by":"publisher","first-page":"8221","DOI":"10.1038\/s41467-023-44016-1","volume":"14","author":"J Wallach","year":"2023","unstructured":"Wallach J et al (2023) Identification of 5-HT2A receptor signaling pathways associated with psychedelic potential. Nat Commun 14:8221","journal-title":"Nat Commun"},{"key":"7170_CR118","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1007\/s11469-024-01253-9","volume":"22","author":"B Weiss","year":"2024","unstructured":"Weiss B et al (2024) Unique psychological mechanisms underlying psilocybin therapy versus escitalopram treatment in the treatment of major depressive disorder. Int J Ment Health Addict 22:806\u2013841","journal-title":"Int J Ment Health Addict"},{"key":"7170_CR119","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1177\/02698811231209194","volume":"38","author":"D Wolinsky","year":"2024","unstructured":"Wolinsky D, Barrett FS, Vandrey R (2024) The psychedelic effects of cannabis: a review of the literature. J Psychopharmacol 38:49\u201355","journal-title":"J Psychopharmacol"},{"key":"7170_CR120","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1038\/s44159-024-00345-6","volume":"3","author":"DB Yaden","year":"2024","unstructured":"Yaden DB, Goldy SP, Weiss B, Griffiths RR (2024) Clinically relevant acute subjective effects of psychedelics beyond mystical experience. Nat Rev Psychol 3:606\u2013621","journal-title":"Nat Rev Psychol"},{"key":"7170_CR121","doi-asserted-by":"publisher","first-page":"54","DOI":"10.3389\/fnint.2018.00054","volume":"12","author":"F Zamberlan","year":"2018","unstructured":"Zamberlan F et al (2018) The varieties of the psychedelic experience: a preliminary study of the association between the reported subjective effects and the binding affinity profiles of substituted phenethylamines and tryptamines. Front Integr Neurosci 12:54","journal-title":"Front Integr Neurosci"},{"key":"7170_CR122","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.ejphar.2007.03.027","volume":"565","author":"MP Zeidan","year":"2007","unstructured":"Zeidan MP, Zomkowski ADE, Rosa AO, Rodrigues ALS, Gabilan NH (2007) Evidence for imidazoline receptors involvement in the agmatine antidepressant-like effect in the forced swimming test. Eur J Pharmacol 565:125\u2013131","journal-title":"Eur J Pharmacol"}],"container-title":["Psychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00213-026-07170-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00213-026-07170-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00213-026-07170-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T19:02:17Z","timestamp":1790708537000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00213-026-07170-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,29]]},"references-count":122,"alternative-id":["7170"],"URL":"https:\/\/doi.org\/10.1007\/s00213-026-07170-0","relation":{},"ISSN":["0033-3158","1432-2072"],"issn-type":[{"value":"0033-3158","type":"print"},{"value":"1432-2072","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,29]]},"assertion":[{"value":"25 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"DB is a scientific advisor for MindState Design Labs, LLC (MDL) and has received fees and shares from the company. FSB is a scientific advisor for MDL and WavePaths, Ltd, and has provided consultation for Gilgamesh Pharmaceuticals, Inc. and has received fees or shares from these companies. RCH is a scientific advisor to Tryp Therapeutics, Osmind, Entheos Labs, Otsuka, and MDL and has received fees or shares from these companies. TR, JK, LL, PW and AT are all employees of, and have received both payment and shares from MDL. PS has no competing interests. There was no ethics committee approval for this study, as such approval was not applicable, because the study relied on publicly accessible experiential accounts as opposed to recruitment and active participation of consenting individuals.","order":1,"name":"Ethics","label":"Ethics approval and competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}]}}